https://scholars.lib.ntu.edu.tw/handle/123456789/639917
Title: | RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants | Authors: | Nishino, Kazumi JIN-YUAN SHIH Nakagawa, Kazuhiko Reck, Martin Garon, Edward B Carlsen, Michelle Matsui, Tomoko Visseren-Grul, Carla Nadal, Ernest |
Keywords: | Carcinoma; EGFR exon 19 deletion variant; Non–small cell lung; Ramucirumab; Targeted therapy; VEGFR inhibition | Issue Date: | Feb-2024 | Journal Volume: | 5 | Journal Issue: | 2 | Source: | JTO clinical and research reports | Abstract: | EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients with untreated advanced NSCLC and an EGFR-activating mutation. This exploratory analysis evaluated potential associations between EGFR exon 19 deletion (ex19del) variants and clinical outcomes. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/639917 | ISSN: | 26663643 | DOI: | 10.1016/j.jtocrr.2023.100624 |
Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.